Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the Delta variant epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS)
View ORCID ProfileHaruka Maeda, View ORCID ProfileNobuo Saito, View ORCID ProfileAtaru Igarashi, Masayuki Ishida, Kazuya Suami, Ai Yagiuchi, Yuya Kimura, Masaru Komino, Hiromi Arai, Toru Morikawa, Iori Motohashi, Rei Miyazawa, Tetsu Moriyama, Hiroshi Kamura, Mayumi Terada, Osamu Kuwamitsu, Tomoichiro Hayakawa, View ORCID ProfileEiichiro Sando, Yasuji Ohara, Osamu Teshigawara, View ORCID ProfileMotoi Suzuki, View ORCID ProfileKonosuke Morimoto
doi: https://doi.org/10.1101/2022.01.17.22269394
Haruka Maeda
1Department of Respiratory Infections, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan
2Department of Clinical Tropical Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
MD, MPHNobuo Saito
3Department of Microbiology, Faculty of Medicine, Oita University, Oita, Japan
MD, PhDAtaru Igarashi
4Unit of Public Health and Preventive Medicine, Yokohama City University School of Medicine, Kanagawa, Japan
5Department of Health Economics and Outcomes Research, Graduate School of Pharmaceutical Sciences, the University of Tokyo, Tokyo, Japan
PhDMasayuki Ishida
6Chikamori Hospital, Kochi, Japan
MD, PhDKazuya Suami
7Nagoya Ekisaikai Hospital, Aichi, Japan
MDAi Yagiuchi
7Nagoya Ekisaikai Hospital, Aichi, Japan
MDYuya Kimura
8Saiseikai Kurihashi Hospital, Saitama, Japan
MDMasaru Komino
8Saiseikai Kurihashi Hospital, Saitama, Japan
RNHiromi Arai
8Saiseikai Kurihashi Hospital, Saitama, Japan
RNToru Morikawa
9Nara City Hospital, Nara, Japan
MDIori Motohashi
10Kawasaki Municipal Tama Hospital, Kanagawa, Japan
MD, MPHRei Miyazawa
10Kawasaki Municipal Tama Hospital, Kanagawa, Japan
BLTetsu Moriyama
11Moriyama Memorial Hospital, Tokyo, Japan
MDHiroshi Kamura
12Loco Clinic Nakameguro, Tokyo, Japan
MDMayumi Terada
13Nijigaoka Hospital, Nagasaki, Japan
MDOsamu Kuwamitsu
14Gohongi Clinic, Tokyo, Japan
MDTomoichiro Hayakawa
15Hayakawa Internal Medicine Clinic, Fukuoka, Japan
MDEiichiro Sando
16Kita-Fukushima Medical Center, Fukushima, Japan
17Fukushima Medical University, Fukushima, Japan
MD, PhDYasuji Ohara
18Takagi Hospital, Aichi, Japan
MDOsamu Teshigawara
19Mizuho Street Clinic, Aichi, Japan
MDMotoi Suzuki
20Infectious Disease Surveillance Center, National Institute of Infectious Diseases, Tokyo, Japan
MD, PhDKonosuke Morimoto
1Department of Respiratory Infections, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan
MD, PhD![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
- Supplementary Table 1[supplements/269394_file02.pdf]
- Supplementary Figure 1[supplements/269394_file03.pdf]
- Supplementary Figure 2[supplements/269394_file04.pdf]
- Supplementary Figure 3[supplements/269394_file05.pdf]
Posted January 23, 2022.
Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the Delta variant epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS)
Haruka Maeda, Nobuo Saito, Ataru Igarashi, Masayuki Ishida, Kazuya Suami, Ai Yagiuchi, Yuya Kimura, Masaru Komino, Hiromi Arai, Toru Morikawa, Iori Motohashi, Rei Miyazawa, Tetsu Moriyama, Hiroshi Kamura, Mayumi Terada, Osamu Kuwamitsu, Tomoichiro Hayakawa, Eiichiro Sando, Yasuji Ohara, Osamu Teshigawara, Motoi Suzuki, Konosuke Morimoto
medRxiv 2022.01.17.22269394; doi: https://doi.org/10.1101/2022.01.17.22269394
Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the Delta variant epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS)
Haruka Maeda, Nobuo Saito, Ataru Igarashi, Masayuki Ishida, Kazuya Suami, Ai Yagiuchi, Yuya Kimura, Masaru Komino, Hiromi Arai, Toru Morikawa, Iori Motohashi, Rei Miyazawa, Tetsu Moriyama, Hiroshi Kamura, Mayumi Terada, Osamu Kuwamitsu, Tomoichiro Hayakawa, Eiichiro Sando, Yasuji Ohara, Osamu Teshigawara, Motoi Suzuki, Konosuke Morimoto
medRxiv 2022.01.17.22269394; doi: https://doi.org/10.1101/2022.01.17.22269394
Subject Area
Subject Areas
- Addiction Medicine (329)
- Allergy and Immunology (648)
- Anesthesia (173)
- Cardiovascular Medicine (2484)
- Dermatology (209)
- Emergency Medicine (384)
- Epidemiology (11947)
- Forensic Medicine (10)
- Gastroenterology (714)
- Genetic and Genomic Medicine (3874)
- Geriatric Medicine (358)
- Health Economics (648)
- Health Informatics (2503)
- Health Policy (963)
- Hematology (350)
- HIV/AIDS (812)
- Medical Education (384)
- Medical Ethics (106)
- Nephrology (411)
- Neurology (3638)
- Nursing (204)
- Nutrition (542)
- Oncology (1887)
- Ophthalmology (549)
- Orthopedics (229)
- Otolaryngology (298)
- Pain Medicine (240)
- Palliative Medicine (71)
- Pathology (459)
- Pediatrics (1066)
- Primary Care Research (434)
- Public and Global Health (6305)
- Radiology and Imaging (1335)
- Respiratory Medicine (845)
- Rheumatology (388)
- Sports Medicine (333)
- Surgery (424)
- Toxicology (51)
- Transplantation (179)
- Urology (152)